Filings

Mentions of ESG increased by a CAGR of 35% in the pharmaceutical industry since 2020

Credit: Bert van Dijk/Getty images.

Powered by

The global pharmaceutical industry experienced a 35% rise in compound annual growth rate (CAGR) in company filings mentions of ESG since 2020. Key companies in terms of mentions include Merck, Bayer, and Novartis, according to GlobalData’s analysis of over 13,500 pharmaceutical company filings.  

Notably, since 2020, governance was the most referenced ESG theme in terms of mentions, ahead of environment and social, according to GlobalData's Company Filings database. Mentions related to ESG increased by 30% year-on-year in 2021 and by 16% year-on-year in 2022.

Top five companies by mentions of ESG in the global pharmaceutical industry since 2020

Of the 50 leading companies in the pharmaceutical industry, GlaxoSmithKline Pharmaceuticals had the highest year-on-year increase in references to ESG in 2022. GlobalData identified 640 ESG related sentences in the company's filings in 2022, 1% of all sentences. Meanwhile, Takeda Pharmaceutical had the highest year-on-year increase in references for ESG in 2021. GlobalData identified 819 ESG related sentences in the company's filings in 2021, 1% of all sentences.

Company filings sentiment related to ESG in the global pharmaceutical industry since 2020

GlobalData’s Company Filings Analytics also applies a sentiment weight to reference sentences, based on how positive the sentiment has turned. Sentiment score is based on the level of positivity on a scale of 0 to 1. The average sentiment score for ESG in 2022 was 0.60, which was more positive compared to the average industry sentiment of 0.44.  

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

Global Data’s Company Filings Analytics uses machine learning to uncover key insights and track sentiment across millions of regulatory filings and other corporate disclosures for thousands of companies across the world’s largest industries.

Go to article: Home | Nanoparticle drug delivery research gets a boostGo to article: Editor's letterGo to article: ContentsGo to article: Mimotopes Company InsightGo to article: MimotopesGo to article: BriefingGo to article: News in NumbersGo to article: Latest NewsGo to article: Latest DealsGo to article: Project UpdatesGo to article: NiproGo to article: In DepthGo to article: Covid-19 vaccine success bolsters nanoparticle drug delivery research Go to article: eConsent in clinical trials: What’s on the horizon?Go to article: Breathing easy: How digital inhalers are changing asthma treatmentGo to article: Primate models in pharma: What the future holds Go to article: A decade on, what’s next for CAR-T therapies?Go to article: FDA’s $7bn plan for 2024: Disclose CMOs, restart Cancer MoonshotGo to article: Molnar-Institute Company InsightGo to article: Molnar-InstituteGo to article: Thematic TakeGo to article: Thematic Take: contentsGo to article: ForewordGo to article: ESG is the most important theme of this decadeGo to article: A timeline of corporate ESGGo to article: The most pressing ESG concerns for the pharma industryGo to article: Key trends impacting ESG performance in the healthcare sectorGo to article: Latest news: ESG in pharmaGo to article: Sustainable supply chains: Clinical trials in a new era of limited resourcesGo to article: Increase in DPI use could lead to decreases in greenhouse gas emissionsGo to article: Environmental sustainability innovation: Leading companies in anti-malarial compositionsGo to article: Deal activity related to ESG in the pharmaceutical industry since 2020Go to article: ESG hiring trends in the global pharmaceutical industry since 2020Go to article: ESG patent applications in the global pharmaceutical industry since 2020Go to article: Mentions of ESG in pharmaceutical industry company filings since 2020 Go to article: GlobalData Thematic IntelligenceGo to article: Pharma Sponsored SupplementsGo to article: CfPIEGo to article: ListingsGo to article: EventsGo to article: RankingsGo to article: Buyer's GuidesGo to article: Next issue